TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39343453

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour reduction intervention (1 hour/day reduction)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (continued as usual)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Whole study group
Number of subjects: 64
Study: 39343511

Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab (N+I)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nivolumab (N)
Number of subjects: 66
Study: 39343510

Group type: EXPERIMENTAL
Intervention: Ipilimumab (1 mg/kg intravenously every 6 weeks) plus Nivolumab (240 mg intravenously every 2 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus Nivolumab
Number of subjects: 16
Study: 39343865

Group type: EXPERIMENTAL
Intervention: Daily oral pre-exposure prophylaxis pills
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Monthly dapivirine vaginal ring
Number of subjects: 25
Study: 39343891

Group type: EXPERIMENTAL
Intervention: Various assessments during maternal visits including medical history, diet, physical activity, sleep, perceived stress, and socioeconomic/sociocultural information.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard laboratory tests during maternal visits including glycemic measures, lipids, and renal function.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive research visits for offspring at various ages (6-12 weeks, 4 months, 6 months, 18 months, 2 years, 3 years, 4-5 years, 6-9 years, 10-13 years, 14-17 years) including medical history, anthropometry, developmental assessment, and biochemical tests.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic/epigenetic testing and ultrasound elastography during major visits.
Number of subjects: 0
Study: 39343892

Group type: EXPERIMENTAL
Intervention: Telemedicine (TM) follow-up intervention
Number of subjects: 26
Study: 39343942

Group type: EXPERIMENTAL
Intervention: Exercise intervention (weekly, supervised, 30-45 min sessions, encouraged to accumulate more than 5000 steps per day)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard care only (control group)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 109
Study: 39343969

Group type: EXPERIMENTAL
Intervention: Kinematic control training
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Joint position sense
Number of subjects: 427

Group type: COMPARATOR
Intervention: Comparison between DCD and TD groups
Number of subjects: 427
Study: 39344118

Group type: EXPERIMENTAL
Intervention: CHD men
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: CHD patients
Number of subjects: 827

Group type: COMPARATOR
Intervention: Non-CVD population
Number of subjects: 827
Study: 39344233

Group type: EXPERIMENTAL
Intervention: Cholinergic system dysfunction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholinergic reductions in the extended connectivity between the thalamic complex and the temporal limbic system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholinergic changes in the cerebellum
Number of subjects: 0
Study: 39344281

Group type: EXPERIMENTAL
Intervention: Ganaplacide 200 mg plus LUM-SDF 960 mg (run-in part)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Ganaplacide-LUM-SDF regimens (Part A)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (Part A)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Ganaplacide-LUM-SDF regimens (Part B)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (Part B)
Number of subjects: 446
Study: 39344366

Group type: EXPERIMENTAL
Intervention: DOAC
Number of subjects: 169

Group type: COMPARATOR
Intervention: VKA
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Anticoagulant switching
Number of subjects: 169
Study: 39344509

Group type: EXPERIMENTAL
Intervention: High-risk plaques present
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Calcified plaque burden
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Low-attenuation plaque burden
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: MACE
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 484
Study: 39344637

Group type: EXPERIMENTAL
Intervention: Colchicine treatment (exact dosage and duration not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (exact treatment not specified)
Number of subjects: 0
Study: 39344652

Group type: EXPERIMENTAL
Intervention: HF with mildly reduced EF
Number of subjects: 16562

Group type: EXPERIMENTAL
Intervention: HF with reduced EF
Number of subjects: 16562

Group type: COMPARATOR
Intervention: HF with preserved EF
Number of subjects: 16562
Study: 39345001

Group type: EXPERIMENTAL
Intervention: Patient Self Advocacy Scale (PSAS)
Number of subjects: 111
Study: 39345094

Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib, lenalidomide, and dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39345118

Group type: EXPERIMENTAL
Intervention: BCI therapy for 12 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BCI therapy
Number of subjects: 26
Study: 39345688

Group type: EXPERIMENTAL
Intervention: Oviderm® or Canoderm® (intervention creams)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Decubal® lipid cream (comparator)
Number of subjects: 78
Study: 39345782

Group type: EXPERIMENTAL
Intervention: Adherent vegans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-adherent vegans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adherent omnivores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-adherent omnivores
Number of subjects: 0
Study: 39345833

Group type: EXPERIMENTAL
Intervention: Weekly oral doses of 14,000 IU vitamin D
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study: 39345834

Group type: EXPERIMENTAL
Intervention: Active PBMT associated with MCE
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo PBMT associated with MCE
Number of subjects: 148
Study: 39346010

Group type: EXPERIMENTAL
Intervention: Bowel preparation through a mid-gut tube
Number of subjects: 95

Group type: COMPARATOR
Intervention: Bowel preparation by oral administration
Number of subjects: 95
Study: 39346117

Group type: EXPERIMENTAL
Intervention: Dostarlimab plus carboplatin-paclitaxel
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo plus carboplatin-paclitaxel
Number of subjects: 487
Study: 39346497

Group type: EXPERIMENTAL
Intervention: 12-week tele-exercise program
Number of subjects: 3

Group type: COMPARATOR
Intervention: No tele-exercise (Control Group B)
Number of subjects: 3

Group type: COMPARATOR
Intervention: No tele-exercise (Control Group C)
Number of subjects: 3
Study: 39346668

Group type: EXPERIMENTAL
Intervention: Blood culture diagnostic stewardship strategies
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Top-performing site strategies
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diagnostic stewardship program
Number of subjects: 14
Study: 39347584

Group type: EXPERIMENTAL
Intervention: Liso-cel (autologous, CD19-directed, 4-1BB CAR T-cell product)
Number of subjects: 82
Study: 39347697

Group type: EXPERIMENTAL
Intervention: Mavacamten treatment for 26 weeks starting at 2.5 mg and potentially titrated up to 5 mg at week 14.
Number of subjects: 30
Study: 39347763

Group type: EXPERIMENTAL
Intervention: Home tobacco environment
Number of subjects: 0
Study: 39347788

Group type: EXPERIMENTAL
Intervention: Healthy Minds Program (self-guided meditation app)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 39347889

Group type: EXPERIMENTAL
Intervention: Patients with PAD (148 patients)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Patients without PAD (565 patients)
Number of subjects: 713
Study: 39347926

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q2W
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study: 39348147

Group type: EXPERIMENTAL
Intervention: HPSA + FIT
Number of subjects: 240000

Group type: COMPARATOR
Intervention: FIT alone
Number of subjects: 240000
Study: 39348299

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 0
Study: 39348302

Group type: EXPERIMENTAL
Intervention: Collaborative Care to Alleviate Symptoms and Adjust to Illness
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 101
Study: 39348366

Group type: EXPERIMENTAL
Intervention: Hemp-derived cannabidiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39348419

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplant (HSCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapies for dcSSc
Number of subjects: 0
Study: 39348472

Group type: EXPERIMENTAL
Intervention: Trebananib (30 mg/kg weekly) plus Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 0
Study: 39348664

Group type: EXPERIMENTAL
Intervention: R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: R-CHOP therapy
Number of subjects: 51
Study: 39348677

Group type: EXPERIMENTAL
Intervention: Thrive with Me (TWM) intervention
Number of subjects: 401

Group type: COMPARATOR
Intervention: Weekly email newsletter (control)
Number of subjects: 401
Study: 39348690

Group type: EXPERIMENTAL
Intervention: Personalized 8- to 10-hour time-restricted eating (TRE) intervention for 3 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) nutritional counseling alone
Number of subjects: 108
Study: 39348695

Group type: EXPERIMENTAL
Intervention: Suicide Care (SC)
Number of subjects: 255789

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 255789
Study: 39348705

Group type: EXPERIMENTAL
Intervention: <10 g/dL transfusion strategy
Number of subjects: 3492

Group type: EXPERIMENTAL
Intervention: <9 g/dL transfusion strategy
Number of subjects: 3492

Group type: EXPERIMENTAL
Intervention: <8 g/dL transfusion strategy
Number of subjects: 3492

Group type: EXPERIMENTAL
Intervention: <7 g/dL transfusion strategy
Number of subjects: 3492
Study: 39348893

Group type: EXPERIMENTAL
Intervention: Self-Guided Web-Based Intervention (SGWI)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Self-Guided Web-Based Intervention with Chat Support (SGWI+C)
Number of subjects: 36
Study: 39349050

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE)
Number of subjects: 102
Study: 39349061

Group type: EXPERIMENTAL
Intervention: Neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy (IPI-NIVO-CRT); IPI 1 mg/kg intravenous and NIVO 360 mg intravenous on day-1, followed by chemotherapy plus NIVO 360 mg 3 weeks later; Thoracic radiotherapy was 50 or 60 Gy, in once-daily doses of 2 Gy.
Number of subjects: 30
Study: 39349152

Group type: EXPERIMENTAL
Intervention: Goldspire™ platform (personalized immunotherapy combining whole tumor-derived cells with antisense oligonucleotide IMV-001 against IGF-1R)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment with Goldspire™ and anti-PD-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Goldspire™ platform
Number of subjects: 0
Study: 39349158

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ-23) Overall Summary Scores (OSS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ-23) Clinical Summary Scores (CSS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ-23) OSS and CSS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ-23) scores
Number of subjects: 0
Study: 39349282

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in NSTEMI patients
Number of subjects: 2806

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in STEMI patients
Number of subjects: 2806

Group type: EXPERIMENTAL
Intervention: Optimal secondary prevention therapy at discharge
Number of subjects: 2806

Group type: EXPERIMENTAL
Intervention: In-hospital major bleeding
Number of subjects: 2806

Group type: EXPERIMENTAL
Intervention: In-hospital death
Number of subjects: 2806
Study: 39349374

Group type: EXPERIMENTAL
Intervention: PowerPICC catheter
Number of subjects: 451
Study: 39349375

Group type: EXPERIMENTAL
Intervention: Cook's balloon for labour induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dinoprostone for labour induction
Number of subjects: 0
Study: 39349477

Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 14
Study: 39349554

Group type: EXPERIMENTAL
Intervention: E2 cypionate (5 mg, IM) and micronized P4 (200 mg, PO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo-equivalent
Number of subjects: 10
Study: 39349619

Group type: EXPERIMENTAL
Intervention: Digital information about genetic testing
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Pre-test genetic counselling consultation
Number of subjects: 1140
Study: 39350021

Group type: EXPERIMENTAL
Intervention: Oral glucose intake during OGTT
Number of subjects: 14
Study: 39350097

Group type: EXPERIMENTAL
Intervention: Guided internet-based self-help programme (Spring)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Delayed treatment control group (access to the programme five months after randomization)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Guided trauma-focused ICBT intervention (both groups)
Number of subjects: 50
Study: 39350107

Group type: EXPERIMENTAL
Intervention: Implants in lateral incisor positions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Implants in canine positions
Number of subjects: 50
Study: 39350120

Group type: EXPERIMENTAL
Intervention: Peer-led intervention (6 weeks of peer-led sessions supervised by nurses)
Number of subjects: 70

Group type: COMPARATOR
Intervention: mHealth application for emotional wellness based on CBT (6 weeks)
Number of subjects: 70
Study: 39350133

Group type: EXPERIMENTAL
Intervention: O-HTN Bundle implementation in outpatient clinics
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: O-HTN Bundle implementation
Number of subjects: 20
Study: 39350137

Group type: EXPERIMENTAL
Intervention: Self-management program (SEMPO) delivered 3-4 months after injury
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Self-management program (SEMPO)
Number of subjects: 220
Study: 39350145

Group type: EXPERIMENTAL
Intervention: Knowledge Insight Tools (KIT)
Number of subjects: 60
Study: 39350156

Group type: EXPERIMENTAL
Intervention: EyeSi simulator training (four two-hour sessions)
Number of subjects: 16
Study: 39350186

Group type: EXPERIMENTAL
Intervention: LSTM-based machine-learning algorithm
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: JOA scores analyzed at 1, 3, 6, and 12 months postoperative
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PASS defined as JOA score ≥ 14.25 at 24 months
Number of subjects: 80
Study: 39350195

Group type: EXPERIMENTAL
Intervention: CCTA-guided strategy
Number of subjects: 3400

Group type: COMPARATOR
Intervention: Traditional cardiovascular risk score-guided strategy (usual care group)
Number of subjects: 3400
Study: 39350201

Group type: EXPERIMENTAL
Intervention: High-UPF Mediterranean diet (3-month intervention)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-UPF Mediterranean diet (3-month control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-UPF Mediterranean diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-UPF Mediterranean diet
Number of subjects: 50
Study: 39350232

Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ringer's Lactate (RL)
Number of subjects: 0
Study: 39350270

Group type: EXPERIMENTAL
Intervention: Dual MSC + MC
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: MC-Only
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control
Number of subjects: 97
Study: 39350291

Group type: EXPERIMENTAL
Intervention: Online home-based group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Gym-based group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Overall experience of participants
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Eligibility and recruitment rates
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 44
Study: 39350292

Group type: EXPERIMENTAL
Intervention: Alberta Family Integrated Care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategic inflection points identified
Number of subjects: 0
Study: 39350322

Group type: EXPERIMENTAL
Intervention: Initial body temperature (BT) >36.8°C in NSTE-ACS patients
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Initial body temperature (BT) in STEMI patients
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Initial body temperature (BT) in NSTE-ACS patients
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 1044
Study: 39350350

Group type: EXPERIMENTAL
Intervention: Blood flow restriction training (BFRT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard of care strength training with a sham unit
Number of subjects: 48
Study: 39350441

Group type: EXPERIMENTAL
Intervention: MyDiaMate intervention for 6 months
Number of subjects: 660

Group type: COMPARATOR
Intervention: Care as usual for 3 months (access after 3 months)
Number of subjects: 660
Study: 39350528

Group type: EXPERIMENTAL
Intervention: Gamified app intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 101
Study: 39350940

Group type: EXPERIMENTAL
Intervention: Augmented soundscape intervention delivered in their room in the morning and evening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 39350954

Group type: EXPERIMENTAL
Intervention: Adjunctive minocycline
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Adjunctive celecoxib
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 39351080

Group type: EXPERIMENTAL
Intervention: COACH intervention with mouthpiece-based head kinematic sensors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control teams fitted with mouthpiece-based head kinematic sensors
Number of subjects: 0
Study: 39351312

Group type: EXPERIMENTAL
Intervention: Preoperative exercise intervention (4-week program including aerobic exercise three times a week, muscle strengthening exercise twice a week, and respiratory muscle exercise once a day)
Number of subjects: 0
Study: 39351353

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention (SUP) - 16-week periodized aerobic and resistance exercise program, performed three days per week, supervised through video conference technology.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Unsupervised exercise (UNSUP) - 16-week, telehealth-based, periodized aerobic and resistance exercise program, performed three days per week, using the same exercise prescription parameters as the SUP group.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Attention control (AC) - 16-week home-based stretching program.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (SUP, UNSUP, AC)
Number of subjects: 45
Study: 39351662

Group type: EXPERIMENTAL
Intervention: IV thrombolysis (IVT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: IVT + mechanical thrombectomy
Number of subjects: 68
Study: 39351676

Group type: EXPERIMENTAL
Intervention: Ultrathin-strut biodegradable-polymer sirolimus-eluting Supraflex Cruz stent
Number of subjects: 741

Group type: COMPARATOR
Intervention: Thin-strut biodegradable-polymer sirolimus-eluting Ultimaster Tansei stent
Number of subjects: 741
Study: 39351703

Group type: EXPERIMENTAL
Intervention: Guided bone regeneration (GBR) using deproteinized bovine bone mineral (DBBM), autologous bone, and a resorbable collagen membrane
Number of subjects: 45
Study: 39351849

Group type: EXPERIMENTAL
Intervention: Patients with severe hypertension and severe hypertensive retinopathy
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Patients with severe retinopathy
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Patients treated without the use of IV therapy
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Patients with normal or low renin level
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Patients not on antihypertensive therapy at enrollment
Number of subjects: 302
Study: 39351881

Group type: COMPARATOR
Intervention: Moderate-dose vitamin D (3200 IU/day)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (5000 IU/day to 7943 IU/day)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314

Group type: COMPARATOR
Intervention: Moderate-dose vitamin D (800 IU/day to 2000 IU/day)
Number of subjects: 314
Study: 39351902

Group type: EXPERIMENTAL
Intervention: C-CAR066, an autologous fully human anti-CD20 CAR-T therapy, administered as a single intravenous infusion at a target dose of 2.0 × 10^6 CAR-T cells per kg.
Number of subjects: 0
Study: 39351987

Group type: EXPERIMENTAL
Intervention: Probiotic intervention
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Demographic characteristics (age, education, income, partnership status, ethnicity)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Demographic characteristics (Black vs. White participants)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Demographic characteristics (marital status)
Number of subjects: 81
Study: 39352135

Group type: EXPERIMENTAL
Intervention: SPR720, phosphate ester prodrug, oral administration, dosage and duration not specified
Number of subjects: 0
Study: 39352173

Group type: EXPERIMENTAL
Intervention: Coping Long Term with Active Suicide Program (CLASP) post-discharge clinical outreach intervention
Number of subjects: 850

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 850
Study: 39352252

Group type: EXPERIMENTAL
Intervention: AG1® supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39352296

Group type: EXPERIMENTAL
Intervention: Extended partial pulpotomy (E-PP)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Restricted partial pulpotomy (R-PP)
Number of subjects: 81